LifeLabs Launches Signatera, Offering Canadians an Innovative and Personalized Approach to Managing Cancer
TORONTO, ON — LifeLabs is pleased to share the launch of SignateraTM, a highly sensitive, personalized molecular residual disease assay (MRD) test developed by Natera for treatment monitoring and molecular residual disease… Read More